These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 19570025)

  • 41. Leucine-rich repeat kinase 2 binds to neuronal vesicles through protein interactions mediated by its C-terminal WD40 domain.
    Piccoli G; Onofri F; Cirnaru MD; Kaiser CJ; Jagtap P; Kastenmüller A; Pischedda F; Marte A; von Zweydorf F; Vogt A; Giesert F; Pan L; Antonucci F; Kiel C; Zhang M; Weinkauf S; Sattler M; Sala C; Matteoli M; Ueffing M; Gloeckner CJ
    Mol Cell Biol; 2014 Jun; 34(12):2147-61. PubMed ID: 24687852
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity.
    Guo L; Gandhi PN; Wang W; Petersen RB; Wilson-Delfosse AL; Chen SG
    Exp Cell Res; 2007 Oct; 313(16):3658-70. PubMed ID: 17706965
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phosphorylation of LRRK2: from kinase to substrate.
    Lobbestael E; Baekelandt V; Taymans JM
    Biochem Soc Trans; 2012 Oct; 40(5):1102-10. PubMed ID: 22988873
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Advance of the study on LRRK2 gene in Parkinson's disease].
    Zhang Y; Chen S
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Dec; 25(6):657-9. PubMed ID: 19065525
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity.
    West AB; Moore DJ; Biskup S; Bugayenko A; Smith WW; Ross CA; Dawson VL; Dawson TM
    Proc Natl Acad Sci U S A; 2005 Nov; 102(46):16842-7. PubMed ID: 16269541
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
    Kethiri RR; Bakthavatchalam R
    Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A trojan horse for Parkinson's disease.
    Hu Y; Tong Y
    Sci Signal; 2010 Apr; 3(116):pe13. PubMed ID: 20371768
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applications.
    Yue Z; Lachenmayer ML
    Mov Disord; 2011 Jul; 26(8):1386-97. PubMed ID: 21538530
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease.
    Lee BD; Shin JH; VanKampen J; Petrucelli L; West AB; Ko HS; Lee YI; Maguire-Zeiss KA; Bowers WJ; Federoff HJ; Dawson VL; Dawson TM
    Nat Med; 2010 Sep; 16(9):998-1000. PubMed ID: 20729864
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations.
    Sheng Z; Zhang S; Bustos D; Kleinheinz T; Le Pichon CE; Dominguez SL; Solanoy HO; Drummond J; Zhang X; Ding X; Cai F; Song Q; Li X; Yue Z; van der Brug MP; Burdick DJ; Gunzner-Toste J; Chen H; Liu X; Estrada AA; Sweeney ZK; Scearce-Levie K; Moffat JG; Kirkpatrick DS; Zhu H
    Sci Transl Med; 2012 Dec; 4(164):164ra161. PubMed ID: 23241745
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.
    Li T; Yang D; Zhong S; Thomas JM; Xue F; Liu J; Kong L; Voulalas P; Hassan HE; Park JS; MacKerell AD; Smith WW
    Hum Mol Genet; 2014 Dec; 23(23):6212-22. PubMed ID: 24993787
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity.
    Gloeckner CJ; Kinkl N; Schumacher A; Braun RJ; O'Neill E; Meitinger T; Kolch W; Prokisch H; Ueffing M
    Hum Mol Genet; 2006 Jan; 15(2):223-32. PubMed ID: 16321986
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers.
    Brockmann K; Gröger A; Di Santo A; Liepelt I; Schulte C; Klose U; Maetzler W; Hauser AK; Hilker R; Gomez-Mancilla B; Berg D; Gasser T
    Mov Disord; 2011 Nov; 26(13):2335-42. PubMed ID: 21989859
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily.
    Stafa K; Tsika E; Moser R; Musso A; Glauser L; Jones A; Biskup S; Xiong Y; Bandopadhyay R; Dawson VL; Dawson TM; Moore DJ
    Hum Mol Genet; 2014 Apr; 23(8):2055-77. PubMed ID: 24282027
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities.
    Liu M; Dobson B; Glicksman MA; Yue Z; Stein RL
    Biochemistry; 2010 Mar; 49(9):2008-17. PubMed ID: 20146535
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules.
    Gandhi PN; Wang X; Zhu X; Chen SG; Wilson-Delfosse AL
    J Neurosci Res; 2008 Jun; 86(8):1711-20. PubMed ID: 18214993
    [TBL] [Abstract][Full Text] [Related]  

  • 57. LRRK2 and autophagy: a common pathway for disease.
    Manzoni C
    Biochem Soc Trans; 2012 Oct; 40(5):1147-51. PubMed ID: 22988880
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity.
    Nguyen AP; Moore DJ
    Adv Neurobiol; 2017; 14():71-88. PubMed ID: 28353279
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expression of leucine-rich repeat kinase 2 (LRRK2) inhibits the processing of uMtCK to induce cell death in a cell culture model system.
    Cui J; Yu M; Niu J; Yue Z; Xu Z
    Biosci Rep; 2011 Oct; 31(5):429-37. PubMed ID: 21370995
    [TBL] [Abstract][Full Text] [Related]  

  • 60. ERKed by LRRK2: a cell biological perspective on hereditary and sporadic Parkinson's disease.
    Verma M; Steer EK; Chu CT
    Biochim Biophys Acta; 2014 Aug; 1842(8):1273-81. PubMed ID: 24225420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.